Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

  • Sagar Lonial
  • , Rakesh Popat
  • , Cyrille Hulin
  • , Sundar Jagannath
  • , Albert Oriol
  • , Paul G. Richardson
  • , Thierry Facon
  • , Katja Weisel
  • , Jeremy T. Larsen
  • , Monique C. Minnema
  • , Al Ola Abdallah
  • , Ashraf Z. Badros
  • , Stefan Knop
  • , Edward A. Stadtmauer
  • , Yiming Cheng
  • , Michael Amatangelo
  • , Min Chen
  • , Tuong Vi Nguyen
  • , Alpesh Amin
  • , Teresa Peluso
    • Niels W.C.J. van de Donk

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Fingerprint

Dive into the research topics of 'Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology